转移性肾细胞癌患者一线治疗获完全缓解的特征:国际转移性肾细胞癌数据库联盟研究结果
基于国际转移性肾细胞癌数据库联盟,分析1,126例接受免疫肿瘤联合治疗和7,557例接受酪氨酸激酶抑制剂单药治疗的患者,完全缓解率分别为4.6%和3.0%(P=0.005),免疫肿瘤联合治疗获完全缓解的调整比值比为1.56(95%CI 1.11-2.17;P=0.009)。完全缓解与两队列 landmark 后总生存获益独立相关。
要点
- 免疫肿瘤联合治疗组完全缓解率4.6%,酪氨酸激酶抑制剂单药组3.0%,差异有统计学意义(P=0.005)。
- 免疫肿瘤联合治疗组获完全缓解的调整比值比为1.56(95%CI 1.11-2.17;P=0.009)。
- 完全缓解与两队列 landmark 后总生存获益独立相关,调整风险比分别为0.17和0.28。
核心结论
- 真实世界人群中完全缓解率不如临床试验人群高。
- 在获完全缓解的患者中,免疫肿瘤联合治疗队列较酪氨酸激酶抑制剂队列更常见若干不良临床病理特征。
- 完全缓解是总生存良好的指标。
研究设计与样本
- 使用国际转移性肾细胞癌数据库联盟,分析接受一线免疫肿瘤联合治疗或酪氨酸激酶抑制剂单药治疗的可评估疗效患者。
- 共纳入1,126例接受免疫肿瘤联合治疗和7,557例接受酪氨酸激酶抑制剂单药治疗的患者。
- 按RECIST 1.1评估最佳总体缓解,比较基线特征和 landmark 后总生存。
主要发现
- 免疫肿瘤联合治疗组52例(4.6%)和酪氨酸激酶抑制剂单药组223例(3.0%)患者获完全缓解(P=0.005)。
- 免疫肿瘤联合治疗(对比酪氨酸激酶抑制剂单药)获完全缓解的调整比值比为1.56(95%CI 1.11-2.17;P=0.009)。
- 获完全缓解患者中,免疫肿瘤联合治疗队列较酪氨酸激酶抑制剂队列非透明细胞组织学比例更高(15.9%和4.7%;P=0.016)。
- 获完全缓解患者中,免疫肿瘤联合治疗队列较酪氨酸激酶抑制剂队列肉瘤样去分化比例更高(29.8%和13.5%;P=0.014)。
- 获完全缓解患者中,免疫肿瘤联合治疗队列较酪氨酸激酶抑制剂队列多部位转移比例更高(80.4%和50.0%;P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical trials have demonstrated higher complete response rates in the immuno-oncology-based combination arms than in the tyrosine kinase inhibitor arms in patients with metastatic renal cell carcinoma. We aimed to characterize real-world patients who experienced complete response to the contemporary first-line therapies. MATERIALS AND METHODS: Using the International Metastatic Renal Cell Carcinoma Database Consortium, response-evaluable patients who received frontline immuno-oncology-based combination therapy or tyrosine kinase inhibitor monotherapy were analyzed. Baseline characteristics of patients and post-landmark overall survival were compared based on best overall response, as per RECIST 1.1. RESULTS: A total of 52 (4.6%) of 1,126 and 223 (3.0%) of 7,557 patients experienced complete response to immuno-oncology-based and tyrosine kinase inhibitor therapies, respectively (P = .005). An adjusted odds ratio for complete response achieved by immuno-oncology-based combination therapy (vs tyrosine kinase inhibitor monotherapy) was 1.56 (95% CI 1.11-2.17; P = .009). Among patients who experienced complete response, the immuno-oncology-based cohort had a higher proportion of non-clear cell histology (15.9% and 4.7%; P = .016), sarcomatoid dedifferentiation (29.8% and 13.5%; P = .014), and multiple sites of metastases (80.4% and 50.0%; P < .001) than the tyrosine kinase inhibitor cohort. Complete response was independently associated with post-landmark overall survival benefit in both the immuno-oncology-based and tyrosine kinase inhibitor cohorts, giving respective adjusted hazard ratios of 0.17 (95% CI 0.04-0.72; P = .016) and 0.28 (95% CI 0.21-0.38; P < .001). CONCLUSIONS: The complete response rate was not as high in the real-world population as in the clinical trial population. Among those who experienced complete response, several adverse clinicopathological features were more frequently observed in the immuno-oncology-based cohort than in the tyrosine kinase inhibitor cohort. Complete response was an indicator of favorable overall survival.
引用
- Takemura K, Navani V, Ernst MS, et al. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. J Urol. 2022. PMID: 36573926. doi:10.1097/JU.0000000000003132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。